Argent Biopharma Limited has released a press release.
Amended June Quarterly Reports (amended App. 4C)
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Argent Biopharma
- June Quarter Activities and Cash Flow Report
- Long COVID Study Results for ArtemiC Support
- Approvals received for South African CimetrA Clinical Trial
- CimetrA anti-inflammatory pre-clinical study results
- Glioblastoma pre-clinical trial results
Later from Argent Biopharma
- Strategic Acquisition of 40% interest in ZAM Software Ltd
- US$10M Financing Agreement signed with US Financier/Investor
- US$1.2M Tranche 1 Funding Recevied from Mercer
- Study Results - Effects of CannEpil on driving performance
- AMC Holdings Inc places US$1 million ArtemiC order
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma